Market Place
Sourcing Support
Gossamer Bio Announces Inducement Grant Under Nasdaq Rule
11 Nov 2024 //
BUSINESSWIRE
Gossamer Bio Announce Q3 2024 Financial Results & Business Update
07 Nov 2024 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
07 Oct 2024 //
BUSINESSWIRE
Gossamer Bio To Present Data At European Respiratory Society Congress 2024
26 Aug 2024 //
BUSINESSWIRE
Gossamer Bio Announces Q2 2024 Results And Business Update
12 Aug 2024 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
Gossamer To Provide Seralutinib OLE Data At ATS 2024
14 May 2024 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10 May 2024 //
BUSINESSWIRE
Gossamer Bio Q1 2024 Results And Business Update
07 May 2024 //
BUSINESSWIRE
Gossamer Bio and Chiesi partner for pulmonary hypertension treatment
06 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Chiesi and Gossamer Bio collaborate to develop Seralutinib for PAH
06 May 2024 //
PR NEWSWIRE
Gossamer Bio and Chiesi Group collaborate on Seralutinib for pulmonary diseases.
06 May 2024 //
BUSINESSWIRE
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
06 May 2024 //
REUTERS
Gossamer: TORREY Phase 2 Data Published In Lancet Respiratory
03 May 2024 //
BUSINESSWIRE
Gossamer Bio Announces Appointment of Steven D. Nathan to its Board of Directors
12 Mar 2024 //
BUSINESSWIRE
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results
05 Mar 2024 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08 Jan 2024 //
BUSINESSWIRE
Gossamer Bio to Host Webcast to Discuss Seralutinib Open-Label Extension Data
13 Dec 2023 //
BUSINESSWIRE
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
05 Dec 2023 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Dec 2023 //
BUSINESSWIRE
Gossamer Bio Announces Appointment of John Quisel to its Board of Directors
29 Nov 2023 //
BUSINESSWIRE
Gossamer Bio Announces Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Gossamer Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
03 Oct 2023 //
BUSINESSWIRE
Gossamer Bio to Present Results of TORREY FRI Sub-Study at Congress 2023
07 Sep 2023 //
BUSINESSWIRE
Gossamer Bio Announces Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Gossamer to Hold Conference with PAH Experts to Discuss PROSERA Phase 3 Design
24 Jul 2023 //
BUSINESSWIRE
Gossamer Bio Announces $212 Million Private Placement Financing
20 Jul 2023 //
BUSINESSWIRE
Gossamer Bio Announces TORREY Data to be Featured at Conference
18 May 2023 //
BUSINESSWIRE
Gossamer cuts loose staff, ties future to tarnished Merck rival
10 May 2023 //
FIERCE BIOTECH
Gossamer Bio Announces1Q 2023 FYR and Provides Business Update
09 May 2023 //
BUSINESSWIRE
Two patient deaths lead to FDA partial hold for Gossamer trial of lymphoma drug
04 Apr 2023 //
ENDPTS
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results
17 Mar 2023 //
BUSINESSWIRE
Gossamer pauses CNS med enrollment, citing risk-benefit profile
17 Mar 2023 //
FIERCE BIOTECH
Gossamer Announces Seralutinib Meets Endpoint in PII TORREY Study in PAH
06 Dec 2022 //
BUSINESSWIRE
Gossamer touts phase 2 win but investors are wary
06 Dec 2022 //
FIERCEBIOTECH
Gossamer Bio Announces Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Faheem Hasnain forges a $120M private placement. So what did we learn from that?
13 Jul 2022 //
ENDPTS
Gossamer Bio Announces $120 Million Private Placement Financing
13 Jul 2022 //
BUSINESSWIRE
Gossamer Bio to Publish PC Data on Seralutinib’s Potential for PAH
09 Jun 2022 //
BUSINESSWIRE
Gossamer Bio Announces First Quarter 2022 Financial Results
10 May 2022 //
BUSINESSWIRE
Faheem Hasnain acknowledges another setback for the Gossamer pipeline
25 Apr 2022 //
ENDPTS
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study
25 Apr 2022 //
BUSINESSWIRE
Gossamer Bio drops ulcerative colitis programme after study flop
25 Apr 2022 //
FIERCEBIOTECH
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results
03 Mar 2022 //
BUSINESSWIRE
Gossamer Bio to Announce Q4 and Full-Year 2021 Financial Results
28 Feb 2022 //
BUSINESSWIRE
Provention Bio hires early research exec from Gossamer
09 Nov 2021 //
FIERCEBIOTECH
Gossamer Bio Announces Q3 2021 Financial Results, Provides Corporate Update
08 Nov 2021 //
BUSINESSWIRE
Gossamer Bio Adds CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline
11 Oct 2021 //
BUSINESSWIRE
The $165M immunology startup Sheila Gujrathi bet on after Receptos, Gossamer
30 Sep 2021 //
ENDPTS
Gossamer Bio Appoints Bryan Giraudo as COO, in addition to CFO Role
21 Sep 2021 //
BUSINESSWIRE
Gossamer rises 7% following Piper Sandler overweight reinstatement
21 Sep 2021 //
SEEKINGALPHA
Gossamer Bio Announces Second Quarter 2021 Financial Results
09 Aug 2021 //
BUSINESSWIRE
Gossamer Bio to Announce Second Quarter 2021 Financial Results
02 Aug 2021 //
BUSINESS WIRE
Gossamer Bio Announces GB004 Clinical Trial Data Presentations
07 Jul 2021 //
BUSINESSWIRE
Gossamer Bio Announces Appointment of Sandra Milligan to its Board of Directors
14 Jun 2021 //
BUSINESSWIRE
Gossamer Bio CSO hits the exit after turbulent year
20 Apr 2021 //
FIERCEBIOTECH
Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice
16 Apr 2021 //
BUSINESSWIRE
Gossamer Bio Announces Promotion of Caryn Peterson to Executive VP
16 Apr 2021 //
BUSINESSWIRE
Gossamer pushes ahead with failed asthma drug GB001
27 Feb 2021 //
ENDPTS
Gossamer Bio to Host Webcast Focused on GB002 and (PAH) on December 15, 2020
07 Dec 2020 //
BUSINESSWIRE
